Segall Bryant & Hamill LLC Has $34.84 Million Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Segall Bryant & Hamill LLC lifted its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 11.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,113,822 shares of the medical research company’s stock after buying an additional 220,415 shares during the period. Segall Bryant & Hamill LLC’s holdings in NeoGenomics were worth $34,836,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in NeoGenomics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company’s stock worth $234,673,000 after purchasing an additional 195,793 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of NeoGenomics during the 4th quarter worth approximately $453,000. Cibc World Markets Corp acquired a new stake in shares of NeoGenomics during the 4th quarter worth approximately $197,000. Royce & Associates LP increased its stake in NeoGenomics by 5.7% in the fourth quarter. Royce & Associates LP now owns 675,866 shares of the medical research company’s stock valued at $11,138,000 after acquiring an additional 36,390 shares during the last quarter. Finally, Natixis Advisors LLC raised its position in NeoGenomics by 8.8% during the fourth quarter. Natixis Advisors LLC now owns 36,976 shares of the medical research company’s stock valued at $609,000 after purchasing an additional 2,994 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

Analyst Upgrades and Downgrades

NEO has been the topic of a number of research analyst reports. Jefferies Financial Group assumed coverage on NeoGenomics in a report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 target price on the stock. Piper Sandler reduced their price objective on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC lowered their target price on NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Bank of America reduced their price target on shares of NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. Finally, Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, NeoGenomics currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.60.

NeoGenomics Price Performance

NEO stock opened at $10.16 on Tuesday. The company has a market capitalization of $1.31 billion, a P/E ratio of -16.39 and a beta of 1.28. The company has a fifty day moving average price of $12.29 and a 200-day moving average price of $14.52. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. NeoGenomics, Inc. has a 52-week low of $8.98 and a 52-week high of $19.12.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The company had revenue of $172.00 million for the quarter, compared to the consensus estimate of $173.40 million. As a group, equities analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.